{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-002863","form_type":"8-K","ticker":"CMPX","cik":"0001738021","company_name":"Compass Therapeutics, Inc.","filed_at":"2021-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.894121+00:00","generated_at":"2026-06-28T14:23:02.597328+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Compass Therapeutics prices $125M public offering of 35.7M shares at $3.50; uplists to Nasdaq","bullets":["Underwritten public offering of 35,715,000 shares at $3.50/share; underwriters have 30-day option for additional 5,357,250 shares.","Gross proceeds ~$125M; net proceeds after discounts and expenses ~$117.3M.","Common stock to trade on Nasdaq Capital Market under ticker CMPX starting November 2, 2021.","SVB Leerink is book-running manager; Raymond James, Wedbush, H.C. Wainwright as passive book-runners.","Net proceeds to fund ongoing operations including clinical trials."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-002863","json":"https://secwatch.observer/filing/0000950170-21-002863.json","markdown":"https://secwatch.observer/filing/0000950170-21-002863.md","text":"https://secwatch.observer/filing/0000950170-21-002863.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1738021/000095017021002863/0000950170-21-002863-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1738021/000095017021002863/cmpx-20211101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T14:23:02.597328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}